BioNxt Solutions Files EU Clinical Trial Application for Sublingual Cladribine
BioNxt Solutions Inc. (CSE:BNXT) submitted a Clinical Trial Application in the European Union via the Clinical Trials Information System. Alongside the regulatory submission, the company completed Good Manufacturing Practice production of approximately 1,500 sublingual cladribine oral dissolvable films.
The manufactured batch is intended for a planned pharmacokinetic bioequivalence study comparing BioNxt's sublingual formulation against Mavenclad. Moving toward human clinical testing represents a key development step under the European Union's hybrid approval pathway. Producing trial supplies in advance helps reduce potential execution delays ahead of the study start.
Regulatory review of the application is expected to take around three months. Before clinical testing can begin, the manufactured batch must also pass quality control testing for final release. Investors will be watching for regulatory authorization and quality control approval as key milestones toward starting the trial.
Key points
- BioNxt Solutions Inc. submitted an EU Clinical Trial Application for its sublingual cladribine oral dissolvable film.
- The company completed Good Manufacturing Practice production of about 1,500 cladribine films for clinical testing.
- The upcoming trial will evaluate bioequivalence against Mavenclad under a European hybrid regulatory pathway.
- Regulatory review of the application is estimated to take approximately three months.
- Trial initiation remains subject to regulatory authorization and quality control batch release.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What did BioNxt Solutions file in the European Union?
BioNxt Solutions submitted a Clinical Trial Application in the EU for a bioequivalence study of its sublingual cladribine oral dissolvable film compared to Mavenclad.
How many cladribine films were manufactured for the study?
The company completed Good Manufacturing Practice production of approximately 1,500 sublingual cladribine films for the trial supply.
When could the BioNxt clinical trial begin?
Regulatory review of the application is expected to take about three months. The study can start after regulatory authorization and quality control batch release.